임상교실 - 교수진 소개

김병수 교수

김병수 교수

김병수 / Byung-Soo Kim

  • 소속내과학교실
  • 직위교수
  • 세부전공혈액종양내과
  • 연구실위치
  • 구내전화번호안5458
  • 팩스
  • 이메일kbs0309@korea.ac.kr
학력사항
198103~198702 고려대학교 의학사
198803~199002 고려대 대학원 의학(세부전공:내과) 의학석사
199003~199602 고려대 대학원 의학(세부전공:혈액종양) 의학박사
200003~200208 고려대 보건대학원 보건학(세부전공: 보건정책및병원경영) 보건학석사
교육 및 경력사항
201201 고려대안암병원 교육수련위원장
200911 고려대학교 줄기세포연구소 소장
200911 고려대안암병원 IRB 위원장
200905~201103 고려대안암병원 임상시험센터 임상시험부장
201103 고려대안암병원 임상시험센터 교육부장/QA실장
200711 고려대안암병원 종양혈액내과 과장
200809~201112 고려대학교 의과대학 교수학습지원센터장
200710~201112 고려대학교 의과대학 교육부학장
200710~201008 고려대학교 대학원 부원장(의무)
200703~201102 고려대학교 의학교육학교실 주임교수
200703~200707 고려대안암병원 JCI 인증 TFT 팀장
200603 고려대학교 IRB 위원
200311~200510 고려대안암병원 적정진료관리 위원회 위원장
200403~200509 고려대 의료원 원가구축 TFT 팀장
201205 보건산업진흥원 R&D 진훙본부 중개연구단장
201204 한국줄기세포학회 이사회 일반이사
201106 의료기관평가 인증원 평가인증팀 현장평가팀장
201105~201204 보건산업진흥원 R&D 진훙본부 PM운영위원
201102 대한혈액학회 교과서편찬 위원회 위원
201005 교육과학기술부 약학 제도 개선 위원회 위원
201002~201104 경기개발연구원 CEO 평가단 위원(2010), 부단장(2011)
201003 대한내과학회 평의원회 평의원
200909~200910 한국의학교육 평가원 의과대학평가단 평가위원
200909 질병관리본부 줄기세포주 등록위원회 위원
200909 한국기관윤리 심의협의회 평가국 현장평가위원장
200906~201005 교육과학기술부 의치의학 제도 개선 위원회 위원
200810 보건복지부 생명윤리교육 평가전문위원회 위원
200805 한국 의과대학의학전문대학원협의회 (KAMC) 전문위원회 위원
200708~200709 Western IRB Trainee
200703 대한조혈모세포이식학회 평의원회 평의원
200703 대한혈액학회 평의원회 평의원
200603~200702 Memorial- Sloan Kettering Cancer Center Malcolm AS Moore's Lab Visiting Scholar
200503~200602 대한혈액학회 이사회 무임소이사
200206~200305 삭품의약안전청 우수조직관리 기준검토협의체 위원
200009 한국조혈모세포은행협회 이식조정위원회 위원
학술활동
20120315 PLACENTA-DERIVED CELL-CONDITIONED CULTURE MEDIA AND ANIMAL-FREE, FEEDER-FREE METHOD FOR CULTURING STEM CELLS USING THE SAME 출원 (미국(USA))
20120314 인간 태반 유래 지지 세포를 이용한 인간 배아줄기세포의 배양 방법 및 그 배양 배지 특허결정 (대한민국)
20120314 인간 태반 유래 지지 세포를 이용한 생쥐 배아줄기세포의 배양 방법 및 그 배양 배지 특허결정(대한민국)
20100902 인간 태반 중간엽줄기세포를 이용한 인간 골수 및 제대혈 단핵세포로부터 CD34+ 조혈모세포 또는 CD14+ 단핵구로의 분화배양 방법 등록(대한민국)
20070509 병원그룹 및 단위 병원 원가관리 방법, 그 장치 및 시스템 등록(대한민국)
20061011 텔로머라제억제 siRNA 발현벡터 및 이를 이용한 유전자치료제 등록(대한민국)
20061011 안티센스 텔로머라제를 생산하는 아데노바이러스 및 이를 이용한 배아줄기세포로부터 조혈모세포의 분화 유도 및 증식 방법 등록(대한민국)
대표논문
  • uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line./200601

  • Acute arthritis of carpal bones secondary to metastatic gastric cancer./200603

  • The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease/201003

  • Human placenta-derived feeders support prolonged undifferentiated propagation of a human embryonic stem cell line, SNUhES3: comparison with human bone marrow-derived feeders./200706

  • Mesenchymal stem cells derived from human chorionic plate may promote hematopoietic differentiation of the human embryonic stem cell line SNUhES3./200703

  • Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma./201010

  • Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFkappaB and Bcl-X L./200806

  • Persistent anemia in a patient with diffuse large B cell lymphoma: pure red cell aplasia associated with latent Epstein-Barr virus infection in bone marrow./200709

  • Successful control of steroid-intolerant Evans' syndrome associated with allogeneic peripheral blood hematopoietic stem cell transplant by rituximab/201103

  • Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type./200708

  • The Bone Morphogenesis Protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer./200809

  • Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer./200702

  • Undifferentiated propagation of the human embryonic stem cell lines, H1 and HSF6, on human placenta-derived feeder cells without basic fibroblast growth factor supplementation./201011

  • Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma./200607

  • Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma :analysis of efficacy and toxicity/201201

  • Cardiac cell therapy with mesenchymal stem cell induces cardiac nerve sprouting, angiogenesis, and reduced connexin43-positive gap junctions, but concomitant electrical pacing increases connexin43-positive gap junctions in canine heart./201006

  • Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study./200902

  • Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas./200901

  • Forced expression of HoxB4 enhances hematopoietic differentiation by human embryonic stem cells/200806

  • Stemness evaluation of mesenchymal stem cells from placentas according to developmental stage: comparison to those from adult bone marrow/201010

  • Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: does it have a prognostic value?/200808

  • Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area./200711

  • Human feeder cells can support the undifferentiated growth of human and mouse embryonic stem cells using their own basic fibroblast growth factors/201111

  • Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma/201104

  • Esophageal involvement by extranodal natural killer T cell lymphoma, nasal type, mimicking Ebstein Barr viral esophagitis in a tonsillar lymphoma patient undergoing chemoradiation therapy./201009

  • Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study./200607

  • Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity./201008

  • Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue./200711

  • Drug resistance to 5-FU linked to reactive oxygen species modulator 1./200707

  • Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients./201012

  • Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy./200809

  • Serum deprivation-induced reactive oxygen species production is mediated by Romo1./201002

  • Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib./201007

  • Korean Multiple Myeloma Working Party. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma./200808

  • Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis./200902

  • The efficacy of human placenta as a source of the universal feeder in human and mouse pluripotent stem cell culture./201006

  • Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia./200705

  • Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity./200704

  • Korean Multiple Myeloma Working Party. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry./200910

  • Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study./200912

  • Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation./200906
  • 목록